Funder: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 766030, the Cancer Research UK Cambridge Institute with core grant C14303/A17197, and the Mark Foundation for Cancer Research and Cancer Research UK Cambridge Centre (C9685/A25177).High-grade serous ovarian cancer lesions display a high degree of heterogeneity on CT scans. We have recently shown that regions with distinct imaging profiles can be accurately biopsied in vivo using a technique based on the fusion of CT and ultrasound scans
UNLABELLED: With the genomic revolution in the early 1990s, medical research has been driven to stud...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
openOvarian cancer kills more than 40 000 women in Europe and more than 150 000 women globally each ...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Funder: Horizon 2020; doi: http://dx.doi.org/10.13039/501100007601Funder: Cancer Research UKFunder: ...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
Background: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffi...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffic...
Acknowledgements: We dedicate this work to the memory of Prof. Naveena Singh, whose invaluable contr...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
UNLABELLED: With the genomic revolution in the early 1990s, medical research has been driven to stud...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
openOvarian cancer kills more than 40 000 women in Europe and more than 150 000 women globally each ...
PURPOSE: To develop a precision tissue sampling technique that uses computed tomography (CT)-based r...
Funder: Horizon 2020; doi: http://dx.doi.org/10.13039/501100007601Funder: Cancer Research UKFunder: ...
BACKGROUND: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
Background: Ovarian cancer survival rates have not changed in the last 20 years. The majority of cas...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffi...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
BackgroundHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most prevalent and lethal subtype of ov...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffic...
Acknowledgements: We dedicate this work to the memory of Prof. Naveena Singh, whose invaluable contr...
Purpose: Develop an integrated intra-site and inter-site radiomics-clinical-genomic marker of high g...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
UNLABELLED: With the genomic revolution in the early 1990s, medical research has been driven to stud...
Therapeutic ultrasound (US) can be noninvasively focused to activate drugs, ablate tumors and delive...
openOvarian cancer kills more than 40 000 women in Europe and more than 150 000 women globally each ...